Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus SOLATENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus SOLATENE.
ARAZLO vs SOLATENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Solatene is a carotenoid that acts as an antioxidant and a precursor to vitamin A. It is thought to absorb light and protect the skin from UV-induced damage, though its exact mechanism in erythropoietic protoporphyria (EPP) involves increasing skin tolerance to sunlight by reducing photosensitivity.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Intravenous: 200 mg bolus over 5 minutes, then 1.6 mg/min continuous infusion for 24 hours. Oral: 80 mg three times daily.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged up to 20-30 hours in end-stage renal disease
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Approximately 65% renal (unchanged drug) and 35% hepatic metabolism followed by biliary/fecal elimination. Renal excretion via glomerular filtration and active tubular secretion
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid